Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
about
Metformin and body weightInsulin detemir versus insulin glargine for type 2 diabetes mellitusLong-acting insulin analogue versus another long-acting insulin analogue for type 2 diabetes mellitusInsulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analoguesThe PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?Metformin Use Is Associated with Reduced Incidence and Improved Survival of Endometrial Cancer: A Meta-Analysis.Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.Aerobic exercise in obese diabetic patients with chronic kidney disease: a randomized and controlled pilot study.Predictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy.Current status of glycemic control of patients with diabetes in Korea: the fifth Korea national health and nutrition examination survey.The evolving place of incretin-based therapies in type 2 diabetesIs the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysisAssociation of vitamin B12 deficiency and metformin use in patients with type 2 diabetes.Glycemic control: a combination of lifestyle management and the use of drugsAnalysis of insulin doses of Chinese type 2 diabetic patients with intensive insulin treatment.Obesity independently predicts responders to biphasic insulin 50/50 (Humalog Mix50 and Insuman Comb 50) following conversion from other insulin regimens: a retrospective cohort studyPharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes StudyOral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetesSaxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trialDevelopment and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.A High Level of Patient Activation Is Observed But Unrelated to Glycemic Control Among Adults With Type 2 Diabetes.The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions.Adenylyl Cyclase Type 5 Deficiency Protects Against Diet-Induced Obesity and Insulin ResistancePharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan.Managing Diabetes Mellitus: A Survey of Attitudes and Practices Among Family PhysiciansTreatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog.Determinants of vascular function in patients with type 2 diabetes.Metformin and its clinical use: new insights for an old drug in clinical practice.Insulin resistance and levels of adipokines in patients with untreated early rheumatoid arthritisMetformin: A candidate for the treatment of gynecological tumors based on drug repositioning.Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?Metformin: an old but still the best treatment for type 2 diabetes.Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes.Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease.Optimizing the therapeutic benefits of exercise in Type 2 diabetes.Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004.Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.Is type 2 diabetes a surgical disease?
P2860
Q22250988-71C632CC-D759-4297-A5C3-B4750AF7FF56Q24235596-411F8894-8DAA-4188-8D18-C148F7093DEAQ24243694-F2399CB6-0C68-412B-B52A-970F3A444959Q26861313-D8C5665C-583D-458E-AEC9-ECCF76FC36B5Q28222372-F3E96D4E-C2FE-4B76-BF65-17FC1F27A1F8Q30234811-2E11D789-C156-4E7E-8EDE-CED1ED58CA3EQ30426632-2243086C-DF9B-4F61-AC44-2C086D715F69Q33552655-0DEBEDE9-1431-44E8-901A-3FFA6D218FD1Q33609805-ACF91A19-2CFF-4115-8BFA-E3D4C2527690Q33850320-6998F3CD-8867-4437-B393-67CE9D19ABD1Q33866808-9747E79D-89D7-4714-B1AA-BE310D794169Q33880174-06C2FC97-7486-4393-9AA0-7F90AFEA1FE3Q33913744-53E7ADDA-EC62-4713-B14E-ACE2BD72784AQ33936137-440782B6-FCA3-4F67-A21B-EE6459D1E385Q34312012-93E8AE2C-9513-4086-9172-3A1DB4E576C2Q34419149-F1A43FA0-C974-4309-967F-E32753B6AE00Q34422081-0BF2F883-EE6F-490D-BF43-1C9B8A11FE1DQ34592210-71FA84E9-73AC-4B88-AF23-96BF5589BBB1Q34606070-C0C2450B-66F3-47F6-AB02-8EDC2AECA239Q34610019-C93CFB9A-5182-4577-9561-B617B12DAC4FQ35214420-4248D070-C3EA-4CEF-9E19-A0925767A3C5Q35626189-81340C17-5F1E-4478-9B33-5C758EE3B378Q35688754-091CBCD1-D9F5-456B-9176-E62327A6BA28Q35769605-0CBE4A76-FC44-4106-B2C0-A31E21C5B5AEQ35997284-5AD75409-E112-4571-B77F-B1695749912FQ36017120-F8FC55A5-5755-4137-AE9B-9B29517CF38FQ36139042-585E52E2-B121-412A-B22E-64EDF007BF83Q36376525-40A95ACD-FD17-48DC-A01A-78F275D2B92EQ36423076-65C9F081-99D3-459A-85CC-24E7A809ED64Q36456346-02026210-12B5-42BC-B726-80B8B70AD96EQ36524748-4E83534C-A98C-406A-ADFD-C08EA94725AEQ36678584-999F2563-BE84-4BE0-8378-CB1A8BB96A7AQ36715464-A2E434A3-8AE0-4CCF-A089-CF62C9767B1FQ36764031-C3BC7CA9-85B3-4886-A4D9-5B0B646332D1Q36822640-59FCB7BC-4714-4E4B-941C-ACF46D2E6089Q36835841-9B5F6CB6-5508-48D6-9C48-DC3F12D5314EQ36893385-B2D2A6DB-6C85-4126-8B62-854741009593Q36906228-F6486ECF-B03A-40FD-BE24-4B9E32AB2626Q36929947-B0ED8236-713C-4CF1-B10A-B40E0C36DD28Q36952728-1C7D6E40-A49C-4471-8981-68646A0B46B7
P2860
Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Management of hyperglycaemia i ...... ion for the Study of Diabetes.
@ast
Management of hyperglycaemia i ...... ion for the Study of Diabetes.
@en
type
label
Management of hyperglycaemia i ...... ion for the Study of Diabetes.
@ast
Management of hyperglycaemia i ...... ion for the Study of Diabetes.
@en
prefLabel
Management of hyperglycaemia i ...... ion for the Study of Diabetes.
@ast
Management of hyperglycaemia i ...... ion for the Study of Diabetes.
@en
P2093
P2860
P1433
P1476
Management of hyperglycaemia i ...... tion for the Study of Diabetes
@en
P2093
D M Nathan
European Association for the Study of Diabetes
M B Davidson
Professional Practice Committee, American Diabetes Association
P2860
P2888
P304
P356
10.1007/S00125-006-0316-2
P577
2006-08-01T00:00:00Z